Search · four archives
Search · four archives
18 papers · ranked by Valyu relevance
Efstratios N Koletsis, Christos Prokakis, Menelaos Karanikolas, Efstratios Apostolakis + 1 more
'Efstratios Apostolakis' 'Dimitrios Dougenis'] Small cell lung carcinoma represents 15-20% of lung cancer. Is is characterized by rapid growth and early disseminated disease with poor outcome. For many years surgery was considered a contraindication in Small Cell Lung Cancer (SCLC) since radiotherapy and…
Guoli Cheng, Yizong Wang, Dianguo Dong, Wenjie Zhang + 2 more
'Zhaojun Wan'] This study aimed to evaluate the efficacy and safety of iodine 125 (125I) radioactive seed implantation for small cell lung cancer at the limited stage of relapse as second line therapy. We collected 6 patients with recurred limited stage small cell lung cancer, who got pathological diagnosis after a…
N. Rodríguez de Dios, M. Murcia-Mejía
Small-cell lung cancer (SCLC) accounts for 13% of all lung tumors. The standard treatment in patients with limited-stage (LS) disease is thoracic radiotherapy (TRT) combined with chemotherapy. In extensive-stage (ES) SCLC, the importance of consolidation TRT in patients with a good treatment response has become…
Michael Stokes, Noami Berfeld, Alicia Gayle, Andrew Descoteaux + 2 more
'Oscar Rohrmoser' 'April Franks'] Title: Background: Robust evidence from real-world studies is needed to aid decision-makers and other stakeholders in choosing the best treatment options for patients. The objective of this work was to assess real-world outcomes of treatment strategies for limited- and extensive-stage…
Charles Ricordel, Laura Chaillot, Efstathios-Iason Vlachavas, Marianthi Logotheti + 14 more
Circulating Tumor Cells (CTC) have been studied in various solid tumors. However, clinical utility of CTC in Small Cell Lung Cancer (SCLC) remains to be demonstrated. Most published studies are based on Cellsearch® isolation methods that did not capture CTC undergoing epithelial-mesenchymal transition. The aim of the…
Evgenii Skurikhin, Olga Pershina, Mariia Zhukova, Darius Widera + 6 more
'Natalia Ermakova' 'Edgar Pan' 'Angelina Pakhomova' 'Sergey Morozov' 'Aslan Kubatiev' 'Alexander Dygai'] Despite the increasing urgency of the problem of treating small cell lung cancer (SCLC), information on the causes of its development is fragmentary. There is no complete understanding of the features of antitumor…
Alessandro Dal Maso, Federica Ferrarini, Giovanni Esposito, Sonia Anna Minuzzo + 14 more
'Sonia Anna Minuzzo' 'Anna Maria Puggia' 'Federica Pezzuto' 'Elisabetta Zulato' 'Loc Carlo Bao' 'Mattia De Nuzzo' 'Alessandra Ferro' 'Stefano Frega' 'Giulia Pasello' 'Fiorella Calabrese' 'Matteo Fassan' 'Federico Rea' 'Valentina Guarneri' 'Stefano Indraccolo' 'Laura Bonanno'] Background Small cell lung cancer (SCLC) is…
Jacob Sands, Janakiraman Subramanian
Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive disease with poor 5-year survival. The first-line standard-of-care for ES-SCLC is platinum plus etoposide, along with 1 of the immune checkpoint inhibitors atezolizumab or durvalumab. Although SCLC first-line therapy often leads to rapid responses…
Sk. Kayum Alam, Anuradha Pandit, Li Wang, Britteny A. Thiele + 5 more
Small cell lung cancer (SCLC) is difficult to treat due to its aggressiveness, early metastasis, and rapid development of resistance to chemotherapeutic agents. Here, we show that treatment with a dopamine D_2_ receptor (D_2_R) agonist reduces tumour angiogenesis in multiple in vivo xenograft models of human SCLC…
Ayushi S. Patel, Seungyeul Yoo, Ranran Kong, Takashi Sato + 9 more
Comprehensive genomic analyses of small cell lung cancer (SCLC), the most aggressive form of lung cancer, have revealed near universal loss of tumor suppressors (RB1 and TP53) and frequent genomic amplification of all three MYC family members. The amplification of each Myc family member is mutually exclusive; hence it…
Zhuo Wang, Qing Luo, Jie Wu, Li Lu + 11 more
Combined small-cell lung cancer (cSCLC) is a rare and aggressive subtype of small-cell lung cancer (SCLC) characterized by mixed histology comprising SCLC and non-small cell lung cancer (NSCLC) or large cell neuroendocrine carcinoma (LCNEC) components. Despite its histological heterogeneity and even poorer prognosis…
Akash Saha, Paul Grevitt, Jair Marques Junior, Alex Von Kriegsheim + 6 more
LIMD1 (LIM domains containing 1) is a bona-fide tumour suppressor gene frequently lost during the early stages of non-small cell lung cancer (NSCLC) development, resulting in a worse outcome for LIMD1-deficient patients. LIMD1 deficiency is present in approximately 50% of NSCLC cases, representing at least 21,000…
Ayooluwa Ilesanmi, Gbenga Dairo, Toheeb Balogun, Bibiire Awoyale
Lung cancer is the cancer of the lung's epithelial cells typically characterized by difficult breathing, chest pain, blood-stained coughs, headache, and weight loss. If left unmanaged, lung cancer can spread to other body parts. While several treatment methods exist for managing lung cancer, exploring natural plant…
Hesamoddin Hosseini, Reza Monsefi, Shabnam Shadroo
Lung cancer has been one of the most prevalent disease in recent years. According to the research of this field, more than 200,000 cases are identified each year in the US. Uncontrolled multiplication and growth of the lung cells result in malignant tumour formation. Recently, deep learning algorithms, especially…
Authors not listed
Immuno-oncology, a rapidly evolving field at the forefront of cancer research, leverages the body’s immune system to fight cancer. In this follow up report, we extend our natural language processing (NLP)-based analysis to pinpoint the context of emergence of the previously identified emerging concepts. To achieve this…
Kavita Iyer, Julian Ivanov, Rumiana Tenchov, Krittika Ralhan + 4 more
Rapid and sustained growth in the field of immuno-oncology has resulted in expansion of available scientific literature. Gaining valuable insights and establishing deep and often hidden meaningful connections in such a large body of work is the need of the hour. In this report we summarize our findings from a novel…
Benjamin Schneider, Sébastien Benzekry, Jonathan P. Mochel
First-line antiproliferatives for non-small cell lung cancer (NSCLC) have a relatively high failure rate due to high intrinsic resistance rates and acquired resistance rates to therapy. 57% patients are diagnosed in late-stage disease due to the tendency of early-stage NSCLC to be asymptomatic. For patients first…
Lian Yang, Ming Xiao, Xian Li, Yalan Wang
TTF1 and ΔNp63/p40 have been used to differentiate ADC and SQC in hypofractionated NSCLC because of their sensitivity and specificity. There are few cases where TTF1 and ΔNp63/p40 are expressed together in the same tumour cells, and little is known about the clinicopathological features, treatment and prognosis of such…